Cancer - Oncolytic Viruses

Co-Chairs: Paola Grandi, Ph.D. and Melissa Kotterman, Ph.D.

5:30 PM - 5:45 PM
8: Preclinical Toxicology Assessment of an Oncolytic Measles Virus Armed With H. pylori Immunostimulatory Bacterial Antigen in Preparation for a Phase I Trial in Breast Cancer Patients
Kimberly Viker, Mayo Clinic

5:45 PM - 6:00 PM
9: Validating Secreted IFNβ as an In Vivo Biomarker of Intratumoral Replication of VSV-IFNβ-NIS
Lianwen Zhang, Mayo Clinic

6:00 PM - 6:15 PM
10: Development of Novel Oncolytic Vector Based on Alternative Adenovirus Serotype 6 for Glioblastoma and Breast Cancer Therapy
Margarita Romanenko, Ph.D., University of Minnesota

6:15 PM - 6:30 PM
11: Human Cytomegalovirus Engineered for Glioma Therapy
Haifei Jiang, M.D., Ph.D., Mayo Clinic

6:30 PM - 6:45 PM
12: Virulent Velogenic Newcastle Disease Virus is More Oncolytic Than Attenuated and Lentogenic Newcastle Viruses
Ahmed Majeed Al-Shammari, Ph.D., Mustansiriyah University, Iraqi Center for Cancer and Medical Genetic Research

6:45 PM - 7:00 PM
13: Generation and Characterization of Replication-Competent Oncolytic Foamy Virus Vectors
Karol Budzik, Mayo Clinic

7:00 PM - 7:15 PM
14: An Oncolytic Adenoviral Vector Expressing an Anti-PD-L1 scFv Reduces Tumor Growth in a Melanoma Mouse Model
Maria Vitale, University of Naples


ASGCT Policy Summit

September 22-24, 2021

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.